Alport syndrome: new advances in the last decade

Ji Hyun Kim
1,2

1 Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2 Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea

Alport syndrome (AS) is a progressive hereditary nephritis that is often accompanied by sensorineural hearing loss and ocular abnormalities. It is inherited in three modes of X-linked AS (XLAS), autosomal recessive AS (ARAS), and autosomal dominant AS (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ARAS and ADAS are caused by those in COL4A3 or COL4A4. There is currently no curative treatment for AS; however, angiotensin-converting enzyme inhibitors (ACEi) can improve the outcome of AS. In the past decade, multiple studies have shown that early intervention with ACEi upon isolated microscopic hematuria or microalbuminuria could delay disease progression, and early diagnosis is crucial for early treatment. Therefore, a new classification of AS based on molecular diagnoses has been proposed, including the paradigm shift of re-classifying female “carriers” to “patients” and “thin basement membrane nephropathy” to “ADAS.” In addition, with the detection of COL4A mutations in some patients with biopsy-confirmed IgA nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease of unknown origin, it is suggested that the phenotype of AS should be expanded. In this review, we highlight the landmark studies and guidelines published over the past decade and introduce strategies for early diagnosis and treatment to improve the outcomes of AS.

Keywords: Angiotensin-converting enzyme inhibitor; Early diagnosis; Early medical intervention; Hematuria, benign familial; Nephritis, hereditary

Introduction

Alport syndrome (AS) is a progressive inherited kidney disease often accompanied by sensorineural hearing loss (SNHL) and ocular abnormalities such as lenticus or retinal flecks [1]. Kidney symptoms of AS start with isolated microscopic hematuria, followed by the appearance of microalbuminuria (urine microalbumin-to-creatinine ratio, 30–300 mg/g), which progresses to overt proteinuria and a decline in kidney function [2]. AS, which affects one in approximately 5,000 people, is the second most common cause of inherited kidney failure after autosomal dominant polycystic kidney disease [3]. It accounts for 0.5% of new-onset chronic kidney disease (CKD) stage G5 (glomerular filtration rate [GFR] <15 mL/min/1.73 m² or treatment by dialysis [4]) cases in adults and 12.9% in children [5]. AS is caused by pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes that encode type IV collagen α3, α4, and α5 chains, respectively. Type IV collagen has six different α chains, α1 to α6, which construct triple-helix structures, the major components of the basement membrane. In the embryonic glomerulus, classical chains of the α1-α1-α2 triple helix form the glomerular basement membrane (GBM), and with development, these are gradually replaced by novel chains α3-α4-α5 [6]. Basement membranes of the cochlea and ocular lens have similar type...
IV collagen compositions as the GBM. Since the novel chains of type IV collagen are defective in AS, basement membranes of the glomerulus, cochlea, and ocular lens become progressively defective [5]. Inheritance patterns of AS are X-linked (XLAS; a defect of COL4A5 on chromosome X), autosomal recessive (ARAS), and autosomal dominant (ADAS; defect of COL4A3 or COL4A4 in chromosome 2), comprising 80%, 15%, and 5%, respectively [1,5].

**Inheritance of AS**

**X-linked AS**

Approximately 85% of XLAS patients have a family history of hematuria (with or without proteinuria), kidney failure, or extrarenal manifestations (SNHL or ocular abnormalities). All male patients present with hematuria and early-onset proteinuria, eventually progressing to kidney failure. Ninety percent of patients reached CKD stage G5 by the age of 40 years (median, 25 years) [7]. In males, truncating mutations (rearrangement, nonsense, and frameshift) show a severe phenotype of earlier kidney failure and hearing loss (HL), and non-truncating mutations (in-frame, missense) exhibit a milder phenotype with later kidney failure and HL [7-9]. Hematuria is present in most (>95%) female patients, and proteinuria appears at the median age of 7 years in 75% of females. One-fourth of female patients progress to CKD stage G5 during their lifetime (median age, 65 years), with this progression occurring by the age of 40 years in 15% of them. The phenotype is highly variable in females, ranging from isolated microscopic hematuria with normal kidney function throughout life to kidney failure at a young age [10,11]. SNHL occurs in 90% of males and 12% of females by the age of 40 years [7,10].

**Autosomal recessive AS**

There are no gender differences in the clinical symptoms, incidence, and prognosis of ARAS. Extrarenal symptoms are common. Both males and females exhibit poor prognoses similar to those with XLAS male patients (the median age of onset is 2.5 years for hematuria, 21 years for developing CKD stage G5, and 13–20 years for SNHL) [12,13].

**Autosomal dominant AS**

In general, both males and females have a good prognosis, and the median ages for developing proteinuria and kidney failure are 17 and 70 years, respectively [5,14]. However, the phenotype is very diverse even within a family, from isolated microscopic hematuria to CKD stage G5. Extrarenal symptoms are uncommon. Their pathologic findings can be either thin basement membrane nephropathy (TBMN) or focal segmental glomerulosclerosis (FSGS). Not rarely, patients with ADAS are misdiagnosed as familial FSGS or IgA nephropathy (IgAN) [14].

**Clinical suspicion of AS**

The most common symptom of AS is hematuria, which is persistent in 100% of XLAS male and ARAS patients, and may appear intermittently in approximately 95% of XLAS females and 50% of ADAS patients (GeneReviews). Recurrent gross hematuria (especially following upper respiratory infection) occurs in infancy or early childhood in 40% to 60% of cases, with an average age of 3.5 years in males and 9 years in females. Males without hematuria by the age of 10 years are unlikely to have AS [15]. Importantly, proteinuria does not appear without hematuria [16]. Ocular abnormalities of AS are less sensitive than the associated HL; however, they are more specific, which means that they could be diagnostic. Lenticonus and central fleck retinopathy occur only in AS and are associated with kidney failure before 30 years in male patients with XLAS [17].

**Histologic findings**

Conventionally, the diagnosis of AS was made pathologically; however, this can be challenging. There are no specific light microscopic findings in AS; mesangial proliferation, FSGS, and interstitial infiltration containing lipid-laden foam cells may be observed [18,19]. Electron microscopy findings typically show irregular thickening and thinning of the GBM, lamellation, and splitting in the lamina densa of a “basket-weave” appearance (Fig. 1) [20]. While these findings are very characteristic of AS, they appear later in the course of the condition; therefore, electron microscopy may show only diffuse GBM thinning in young male patients with XLAS or XLAS females, or ARAS/ADAS patients [5,21]. Immunofluorescence staining of type IV collagen α5 can be diagnostic, irrespective of the patient’s age. Typically, collagen type IV α5 chain expression is completely absent in XLAS male patients (both at GBM and Bowman capsule) and ARAS (GBM) patients; however, more than 20% of XLAS males and 20% of ARAS patients exhibit normal expressions of α5 if their pathologic variants are non-truncating [13,22], as well as ADAS patients. XLAS female patients exhibit a mosaic pattern...
Fig. 1. Electron microscopy findings: the glomerular basement membrane (GBM) abnormalities caused by COL4A mutations. The GBM in Alport syndrome (AS) patients demonstrates irregular thickening with abnormal splitting and lamination. In patients with a thin basement membrane lesion, which is currently proposed to be regarded as AS, the GBM shows abnormally diffuse thinning. Reused from Warady et al. [20]. Images were used with permission from J. Charles Jennette. www.unckidneycenter.org. Accessed March 9, 2022.

Fig. 2. Immunofluorescence staining of type IV collagen in glomerulus. (A) Normal control exhibits full expression in both the glomerular basement membrane (GBM) and Bowman capsule (BC). (B) An X-linked Alport syndrome (XLAS) male patient shows entirely negative expression in both GBM and BC. (C) An XLAS female patient displays a mosaic pattern of expression in both GBM and BC. Green and red colors indicate α5 and α2 chains of type IV collagen, respectively. (D) An autosomal recessive AS patient presents negative expression only on GBM, but positivity on BC. Reused from Nozu et al. [1].
of αS staining (Fig. 2) [1]. The collagen type IV αS stain in skin biopsy is valid only for XLAS since the epidermal basement membrane is mainly comprised of the triple helix of αS-αS-αS as the Bowman capsule [23]. Therefore, the normal expression of collagen type IV αS AS cannot exclude AS. Furthermore, non-specific focal GBM thinning may also be seen in IgAN [24]. Thus, kidney biopsy plays a supportive, not confirmatory role in the diagnosis of AS [25].

Advances in the last decade

Due to these limitations of histopathology and the remarkable development of molecular-based techniques in the past decade, genetic testing has become the first-line diagnostic technique for AS. Because COL4A genes are large, targeted next-generation sequencing, including all three novel chain genes, has become the primary genetic screening method instead of Sanger sequencing [3,26]. Although there is currently no curative therapy for AS, nephroprotective drugs such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers can delay the progression to kidney failure for years or even decades. In a large cohort study of XLAS males in Japan [27], kidney replacement therapy (KRT) was delayed by 17 years and 12 years in the non-truncating and truncating mutant groups, respectively, in the group of patients treated with either ACEi or angiotensin receptor blockers compared to those in the untreated group. In addition, multiple prospective and retrospective studies have reported the beneficial effects of early interventions with ACEi. The 2020 guideline emphasizes early molecular diagnosis to enable early treatment and avoid immunosuppression [2].

The rationale for early ACEi treatment

In a study using the mouse model of ARAS, those treated with ramipril at 4 weeks survived twice as long as mice not treated with ramipril, whereas the group that started treatment at 7 weeks did not differ in survival compared to the untreated group [28]. A retrospective cohort study in Europe showed that among those who began treatment when they had only isolated hematuria or microalbuminuria, no one needed KRT until the age of at least 40 years [29]. Treatment initiation when patients had proteinuria (>0.3 g/day) with normal kidney function delayed KRT for 18 years (median age of KRT, 40 years). Later initiation at CKD stage G3 (GFR, 30–59 mL/min/1.73 m²) or G4 (GFR, 15–29 mL/min/1.73 m²) had the effect of postponing KRT by only 3 years (median age, 25 years) compared to the untreated group with a median KRT age of 22 years. Based on these studies, the Early Prospective Therapy European Community Trial in Alport syndrome (EARLY PRO-TECT Alport) was conducted in Germany to determine whether starting ramipril treatment on noticing isolated hematuria or microalbuminuria could delay the progression of the disease to its next phase (microalbuminuria or proteinuria, respectively). Early treated group (n=11, open-label [n=42]) developed disease progression in 27%, 41%, for each, whereas the placebo group (n=9) in 56%. Although not statistically significant, the authors concluded that the early initiation of ramipril might be beneficial in delaying progression by more than 40% [30].

Expanded phenotypes of AS

With the broad implementation of next-generation sequencing, several cases are rediagnosed with AS even when their symptoms are not always compatible with AS. In a large-scale analysis of whole-exome sequencing in 3,315 patients with CKD of all causes 10% were found to have genetic causes, of which 30% were diagnosed as AS with COL4A mutations. The majority of these patients (62%) had been misdiagnosed with hypertensive nephropathy, other kinds of glomerulonephropathy such as steroid-resistant nephrotic syndrome, IgAN, or FSGS [20,31]. COL4A defects were the most common causes in adult-onset FSGS, accounting for up to 20% of familial FSGS [32]. Therefore, the COL4A3-COL4A5 mutations must be considered in CKD of unknown etiology, steroid-resistant nephrotic syndrome, FSGS, and IgAN, even if the clinical manifestations and biopsy findings are not fully compatible with AS, especially if there is a contributive family history [26]. Recent guidelines emphasize that FSGS or IgAN with pathogenic variants of COL4A should be considered “AS” and not as “coincidental disease” [2].

The new classification scheme for AS

From “carrier” to “patient” in XLAS females

Traditionally, females with COL4A5 heterozygous mutations have been considered “carriers.” While previously regarded as benign, 25% of them develop CKD stage G5 during their lifetime. Risk factors for progression include a history of gross hematuria in childhood, proteinuria, nephrotic syndrome, SNHL, and the presence of diffuse thickening and lamellation of the GBM. Therefore, experts stressed that females with COL4A5...
heterozygous mutations should be considered “patients” rather than benign “carriers.” Female AS patients need to be monitored regularly for proteinuria and kidney function [33,34].

From “TBMN” and “ADAS”
TBMN, traditionally known as “benign familial hematuria,” is characterized by hematuria with or without mild proteinuria, with diffuse GBM thinning. This condition was considered a benign one that does not progress to CKD stage G5. However, TBMN, in many cases [35], is caused by heterozygous mutation of COL4A3 or COL4A4, same as “ADAS,” and there had been no definite distinction [5]. Moreover, the progression to CKD stage G5 in TBMN has been reported, especially in patients with risk factors of proteinuria, FSGS, or GBM thickening and lamellation on kidney biopsy, SNHL, and family history of progressive kidney disease [33,36]. So, is TBMN equal to ADAS? A guideline published in 2019 did not agree, as the likelihood of kidney failure is minimal [3]. However, the latest guidelines emphasize that all diseases caused by heterozygous mutations of COL4A3 or COL4A4 should be classified as “ADAS” for an earlier and more aggressive intervention since earlier ACEi treatment delays kidney failure for longer [2,33]. In a recent study, Yamamura et al. [37] reported that ADAS accounted for 17% of all AS cases, which is much higher than the 5% found in previous reports, suggesting that the diagnosis of ADAS is underestimated [37]. Therefore, even when diagnosed with TBMN, especially if associated with COL4A3 or COL4A4 variants, regular follow-up is strongly recommended for the risk of kidney failure.

Early diagnostic tactics

Early genetic test necessity
The latest guideline proposed in 2020 by Kashtan and Gross [2] recommends that genetic testing should be performed if AS is suspected in patients with persistent glomerular hematuria. Kidney biopsy is recommended if genetic testing has uncertain pathogenicity and AS is not suspected based on clinical data or family history. Kidney biopsy should include transmission electron microscopy, and if transmission electron microscopy is not available, immunofluorescence of the type-IV collagen stain is required.

Treatment guidelines

When should we start treatment and how do we monitor it?
The clinical practice recommendations from the Alport Syndrome Research Collaborative emphasize initiating early interventions. In XLAS male and ARAS patients, who progress to CKD stage G5 in 100% of cases, treatment should be started as soon as possible when the diagnosis is obtained in patients older than 1 year regardless of proteinuria (strong recommendation). For XLAS female and ADAS patients, treatment initiation is recommended if microalbuminuria develops during annual monitoring [2]. This differs significantly from their previous guideline in 2013 that did not recommend treatment with isolated hematuria and recommended optional treatment with microalbuminuria in XLAS males [38].

Which drugs should we use?
The drug recommended by the above-mentioned guideline is either ramipril or lisinopril. Ramipril is a well-established drug with evidence of efficacy and safety, which was adopted from protocols in the ESCAPE (Effect of Strict blood pressure Control and ACE Inhibition on the Progression of CKD in Pediatric Patients) trials [39] and the EARLY PRO-TECT trial for children with AS [30]. Lisinopril is another ACEi with a comparable duration of action to that of ramipril, and it has obtained evidence from some pediatric studies [40,41]. In the ARAS mouse model study, ramipril prolonged the lifespan significantly more than candesartan did (111% vs. 38%, respectively) [42]. However, no AS studies in humans have compared ramipril with other drugs. One small study compared the antiproteinuric effects of enalapril to those of losartan in children with AS and found no significant difference between the two [43].

How to increase the dose of the ACEi?
It is emphasized that ACEi should be up titrated more rapidly and aggressively than previously recommended. The previous guideline in 2013 recommended increasing ramipril dose “every” 3 months until the target urine protein-to-creatinine ratio (UPCR; less than half of the baseline value) is reached [38]. However, the recent guideline in 2020 recommends increasing the dose “over” the first 3 to 4 months starting 1 mg/m²/day to a maximum of 6 mg/m²/day of ramipril irrespective of the degree of proteinuria if the patient can tolerate such an increase. The dosage needs to be increased as the child grows to maintain the maximum dose [2].
Dual renin-angiotensin-aldosterone system blockade

Data from the ESCAPE trial in pediatric CKD reported that a UPCR <1.0 mg/mg was associated with better kidney outcomes [44]. Therefore, the latest guideline suggested that considering the use of dual renin-angiotensin-aldosterone system (RAAS) blockade may be reasonable if the UPCR exceeds 10 mg/mg despite the maximum tolerated dose of ramipril or lisinopril. Losartan can be added in small amounts, at an initial dose of 0.8 mg/kg/day [2]. However, there is limited evidence of the efficacy and safety of dual RAAS blockade, and the Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends not using dual blockade in another glomerulopathy. When using dual RAAS blockade, adverse effects such as hyperkalemia, kidney insufficiency, and hypotension should be periodically monitored [2,45].

Cyclosporine

Cyclosporine (CsA) is not recommended in patients with AS [2]. CsA diminishes proteinuria by directly stabilizing the podocyte cytoskeleton [46]; however, the long-term use of this drug may stimulate profibrotic mediators such as transforming growth factor-beta, leading to interstitial fibrosis and tubular atrophy [47]. In small, uncontrolled studies conducted in Spain [48,49], France [50], and Italy [51], proteinuria significantly decreased throughout CsA treatment (5 mg/kg/day). However, the effect was temporary: proteinuria nearly returned to the baseline value after discontinuation in most patients, and kidney outcomes were conflicting with stable GFRs over 8 years [48,49] versus kidney function decline over 6 months, and some patients developed interstitial fibrosis 20 to 27 months after CsA initiation [50].

Hearing and ophthalmologic evaluation and follow-up

HL in children, even in mild cases, affects speech-language, social-behavior, cognitive development, and academic performances [52]. Several papers have shown that HL in AS is sensorineural, progressive, and bilateral, often affecting the middle and particularly high frequencies [53]. Therefore, it can only be detected by formal hearing tests, especially during early childhood. Approximately 30% of XLAS males and 20% of ARAS patients exhibit detectable HL by age 10. In males with XLAS, HL increases to approximately 60% by age 20 and shows a genotype-phenotype correlation. ARAS patients show a high rate of HL when they have one or more truncating mutations [8,13,54]. Therefore, a hearing evaluation is recommended annually for XLAS males and ARAS, starting at the age of 5 to 6 years, and earlier if overt proteinuria occurs or symptoms suggestive of HL, such as speech delay, develop. For XLAS females, the probability of HL is less than 10% by the age of 40 years; however, HL eventually occurs in 30% of them [10]. It is recommended that females with XLAS perform a formal hearing test when overt proteinuria is present. All AS patients should avoid loud sounds. If HL develops, it usually responds well to hearing aids [2].

Ocular abnormalities in AS, lenticonus, and central fleck retinopathy have high diagnostic and prognostic values [17]. For XLAS males with truncating mutations and ARAS patients, it is strongly recommended that ophthalmic investigations begin at age 15 (earlier if they have an abnormal vision) and annual check-ups should be performed. For females with XLAS and ADAS patients, ophthalmologic assessments are recommended if clinically indicated [2].

Other recommendations

Hypertension can accelerate the deterioration of kidney function. Therefore, it should be strictly controlled, and the target blood pressure should be in the 50th percentile [25]. As lifestyle modifications, maintaining a body mass index of <25 kg/m², moderating one’s dietary intake of meat protein and salt, and avoiding smoking are also recommended [2].

Research horizons

Future therapeutic options

In a clinical trial on AS-induced CKD [55], bardoxolone, an activator of nuclear factor erythroid-related factor 2 (Nrf2), improved the GFR. However, another study of this drug in patients with type 2 diabetes mellitus and CKD stage G4 (BEACON trial) was prematurely terminated due to fatal cardiovascular complications (relative risk, 1.83; P<0.001) [56]. For safety and efficacy reasons, the Food and Drug Administration recently denied the approval of the drug in AS.

Other investigational approaches in AS include microRNA-21 antagonists as anti-fibrotic agents and exon-skipping gene therapy. Both were effective in animal studies and are now un-
Conclusions

Advances in molecular genetics and clinical studies over the past decade have made early diagnosis and intervention possible in patients with AS. Also, histopathologic diagnoses other than AS cannot exclude AS, since some of such patients harbor disease-causing variants of AS. Therefore, even when the clinical phenotype and biopsy results are not compatible with AS, the \textit{COL4A3-COL4A5} mutations need to be considered, especially if there is a contributive family history. Female subjects affected by XLAS are no longer considered "carriers" but "patients," and individuals with heterozygous mutations in \textit{COL4A3} and \textit{COL4A4} (even diagnosed with "TBMN") should be monitored regularly due to the risk of kidney failure. XLAS males and ARAS patients older than 12 months need to undergo ACEi regardless of proteinuria, while other types can be monitored for microalbuminuria appearance, which indicates treatment.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

All the work was done by JHK.

References

1. Nozu K, Takaoka Y, Kai H, Takasato M, Yabuuchi K, Yamamura T, et al. Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome. Kidney Res Clin Pract 2020;39:402-13.
2. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults— an update for 2020. Pediatr Nephrol 2021;36:711-9.
3. Savige J, Ariani F, Mari F, Bruttini M, Renieri A, Gross O, et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol 2019;34:1175-89.
4. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Inghelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 2020;97:1117-29.
5. Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 2019;23:158-68.
6. Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, et al. Type IV collagen of the glomerular basement membrane: evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 2000;275:30716-24.
7. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masouni A, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010;21:876-83.
8. Jais JP, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000;11:649-57.
9. Gross O, Netzer KO, Lambrech R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002;17:1218-27.
10. Jais JP, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 2003;14:2603-10.
11. Yamamura T, Nozu K, Fu XJ, Nozu Y, Ye MJ, Shono A, et al. Natural history and genotype-phenotype correlation in female X-linked Alport syndrome. Kidney Int Rep 2017;2:850-5.
12. Lee JM, Nozu K, Choi DE, Kang HG, Ha IS, Cheong HI. Features of autosomal recessive Alport syndrome: a systematic review. J Clin Med 2019;8:178.
13. Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 2014;29:1535-44.
14. Kamiyoshi N, Nozu K, Fu XJ, Morisada N, Nozu Y, Ye MJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol 2016;11:1441-9.
15. Kashtan CE. Alport syndrome: an inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999;78:338-60.
16. Sessa A, Meroni M. Alport’s syndrome: Orphanet encyclopedia [Internet]. Paris: Orphanet; 2001 [cited 2022 Mar 2]. Available from:
Kim. Recent updates of Alport syndrome

17. Savage J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015;10:703-9.
18. Adam J, Connor TM, Wood K, Lewis D, Naik R, Gale DP, et al. Genetic testing can resolve diagnostic confusion in Alport syndrome. Clin Kidney J 2014;7:197-200.
19. Yao XD, Chen X, Huang GY, Yu YT, Xu ST, Hu YL, et al. Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis. Orphanet J Rare Dis 2012;7:100.
20. Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, et al. Alport syndrome classification and management. Kidney Med 2020;2:639-49.
21. Heidet L, Gubler MC. The renal lesions of Alport syndrome. J Am Soc Nephrol 2009;20:2120-5.
22. Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fuj J, Ohtsubo H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int 2014;85:1208-13.
23. Nakanishi K, Yoshikawa N, Iijima K, Kitagawa K, Nakamura H, Ito H, et al. Immunohistochemical study of alpha 1-5 chains of type IV collagen in hereditary nephritis. Kidney Int 1994;46:1413-21.
24. IgA nephropathy combined with thin basement membrane nephropathy in children. Kidney Res Clin Pract 2013;32:194-5.
25. Lennon R, Fornoni A. Could this be Alport syndrome? Clin J Am Soc Nephrol 2021;16:1743-5.
26. Savage J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet 2021;29:1186-97.
27. Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 2020;98:1605-14.
28. Gross O, BeiroWS B, Koeple ML, Kuck J, Reiner M, Addicks K, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003;63:438-46.
29. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012;81:494-501.
30. Gross O, Tonshoff B, Weber LT, Pape L, Latta K, Feihrenbach H, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020;97:1275-86.
31. Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 2019;380:142-51.
32. Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016;31:961-70.
33. Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α35. A position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018;93:1045-51.
34. Grunfeld JP, Noel LH, Hafez S, Droz D. Renal prognosis in women with hereditary nephritis. Clin Nephrol 1985;23:267-71.
35. Rana K, Wang YY, Powell H, Jones C, McCredie D, Buzza M, et al. Persistent familial hematuria in children and the locus for thin base membrane nephropathy. Pediatr Nephrol 2005;20:1729-37.
36. Inafukii A, Nozu K, Sawa N, Nakanishi K, Ubara Y. How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists. Clin Exp Nephrol 2020;24:651-6.
37. Yamamura T, Nozu K, Minamikawa S, Horinouchi T, Sakakibara N, Nagano C, et al. Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome. Mol Genet Genomic Med 2019;7:e883.
38. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013;28:5-11.
39. ESCAPE Trial Group, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361:1639-50.
40. Nakanishi K, Iijima K, Ishikura K, Hayata H, Awazu M, Sako M, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 2009;24:845-9.
41. Gipson DS, Trachtman H, Kaselk FF, Greene TH, Radeva MK, Gasman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868-78.
42. Gross O, Schulz-Lohoff E, Koeple ML, BeiroWS B, Addicks K, Bloch W, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004;19:176-23.
43. Webb NJ, Shahinifar S, Wells TG, Massaad R, Gleim GW, McCravy S, et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol 2013;28:737-
43. 
44. van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wuhl E, Schaefer F, et al. Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 2018;29:2225-33.
45. Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, et al. The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 2006;21:824-9.
46. Paul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8.
47. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508.
48. Callis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int 1999;55:1051-6.
49. Callis L, Vila A, Nieto J, Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport’s syndrome. Pediatr Nephrol 1992;6:140-4.
50. Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007;22:57-63.
51. Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010;25:1269-75.
52. Kim JH, Lee DH, Lee B, Lim SH, Ahn YH, Kang HG, et al. Renal syndromic hearing loss is common in childhood-onset chronic kidney disease. J Korean Med Sci 2020;35:e364.
53. Alves FR, de A Quintanilha Ribeiro F. Revision about hearing loss in the Alport’s syndrome, analyzing the clinical, genetic and bio-molecular aspects. Braz J Otorhinolaryngol 2005;71:813-9.
54. Zhang X, Zhang Y, Zhang Y, Gu H, Chen Z, Ren L, et al. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males. Orphanet J Rare Dis 2018;13:229.
55. Reata Pharmaceuticals. Reata announces positive results from year 2 of the pivotal phase 3 CARDINAL study of bardoxolone methyl in patients with Alport syndrome [Internet]. Reata Plano: Pharmaceuticals; 2020 [cited 2022 Mar 5]. Available from: https://www.reatapharma.com/investors/news/news-details/2020/Reata-Announces-Positive-Results-From-Year-2-of-the-Pivotal-Phase-3-CARDINAL-Study-of-Bardoxolone-Methyl-in-Patients-with-Alport-Syndrome/default.aspx
56. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369:2492-503.
57. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 2015;125:141-56.